//fpnotebook.com/
Antiplatelet Management in Diabetes Mellitus
Aka: Antiplatelet Management in Diabetes Mellitus, Aspirin Use in Diabetes
- See Also
- Antiplatelet Therapy for Vascular Disease
- Background
- Aspirin has historically been considered in all diabetic patients or starting at age 45 years in men and age 55 years in women
- However consider benefit of 7 years Aspirin (1 less CV event in 90) versus life threatening bleeding risk (1 in 110)
- (2018) Presc Lett 25(11): 61
- Indications: Low dose Aspirin 81 mg daily (more specific as of 2012)
- Framingham risk >10%, no vascular disease, and no Bleeding Diathesis
- Males over age 50 years or females over age 60 years and
- One additional Cardiovascular Risk Factor
- Tobacco Abuse
- Hypertension
- Dyslipidemia
- Albuminuria
- Family History of premature cardiovascular death
- Indications: Clopidogrel (Plavix) 75 mg daily
- Known cardiovascular disease
- Adverse Effects
- See Aspirin
- Aspirin does not increase risk of Retinal Hemorrhage